Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug;30(8):1185-1195.
doi: 10.1002/pon.5673. Epub 2021 Apr 20.

A systematic review of fear of cancer recurrence related healthcare use and intervention cost-effectiveness

Jake Thomas Warton Williams  1 , Alison Pearce  1 , Allan 'Ben' Smith  2   3
Affiliations

A systematic review of fear of cancer recurrence related healthcare use and intervention cost-effectiveness

Jake Thomas Warton Williams et al. Psychooncology. 2021 Aug.

Abstract

Objective: Fear of cancer recurrence (FCR) is a common and burdensome psychological condition affecting cancer survivors. This systematic review aims to synthesise current evidence regarding: (1) FCR-related healthcare usage and costs and (2) the cost-effectiveness of FCR treatments.

Methods: We searched MEDLINE, CINAHL, Cochrane and other electronic databases using MeSH headings and keywords for cancer, FCR and costs from their inception to September 2019. Identified studies were screened for eligibility. Original, peer-reviewed journal articles reporting quantitative data from samples of adults treated for cancer written in English were included. Quality was appraised using the Drummond checklist for economic evaluations or the relevant Joanna Briggs Institute Critical Appraisal Tool.

Results: Data from 11 studies were extracted and synthesised. Seven studies addressed the costs of FCR and suggested an increase in the use of primary and secondary healthcare. Four studies addressed the cost-effectiveness of different FCR treatments and suggest that some treatments may cost-effectively reduce FCR and improve quality of life. Reviewed treatments had an incremental cost-effectiveness ratio between AU$3,233 and AU$152,050 per quality-adjusted life year gained when adjusted to 2019 Australian dollars. All studies were of sufficient quality to be synthesised in this review.

Conclusions: FCR appears to be associated with greater use of certain healthcare resources, and FCR may be treated cost-effectively. Thus, appropriate FCR treatments may not only reduce the individual burden, but also the strain on the healthcare system. Further high-quality research is needed to confirm this and ensure the future implementation of efficient and sustainable FCR treatments.

Keywords: cancer; cost-effectiveness; costs; economic evaluation; fear of cancer recurrence; healthcare utilisation; oncology; systematic review.

PubMed Disclaimer

References

REFERENCES

    1. Lebel S, Ozakinci G, Ozakinci G, et al. From normal response to clinical problem: definition and clinical features of fear of cancer recurrence. Support Care Cancer. 2016;24(8):3265-3268.
    1. Armes J, Crowe M, Colbourne L, et al. Patients' supportive care needs beyond the end of cancer treatment: a prospective, longitudinal survey. J Clin Oncol. 2009;27(36):6172-6179.
    1. Baker F, Denniston M, Smith T, West MM. Adult cancer survivors: how are they faring? Cancer. 2005;104(S11):2565-2576.
    1. Mutsaers B, Butow P, Dinkel A, et al. Identifying the key characteristics of clinical fear of cancer recurrence: an international Delphi study. Psycho-Oncology. 2020;29(2):430-436.
    1. Simard S, Savard J. Screening and comorbidity of clinical levels of fear of cancer recurrence. J Cancer Surviv. 2015;9(3):481-491.

Publication types

LinkOut - more resources